|
|
结核病可能在增加FHIT甲基化率的同时会阻碍EGFR突变
|
Abstract:
背景：流行病学研究表明肺癌与结核病之间存在因果关系，尤其患有结核病的患者往往更容易患上肺腺癌，但其中的作用机制尚不清楚。前期研究发现，肺结核患者中EGFR突变和FHIT甲基化水平较高，本研究旨在查明肺腺癌和结核病患者中EGFR突变和FHIT甲基化的遗传相关性。方法：在肺腺癌和肺结核患者中，分析了表皮生长因子受体(EGFR)突变及FHIT基因的甲基化状态，并检查了结核病状态与遗传/表观遗传变异之间的关系。结果：结核患病状态与EGFR突变频率有很强的相关性，而结核患病状态与FHIT甲基化之间的关系较弱。EGFR突变与FHIT甲基化之间呈反相关关系。结论：结核病可能在增加FHIT甲基化率的同时会阻碍EGFR突变，导致患结核病后发展肺腺癌的患者对EGFR抑制剂治疗疗效不佳。
Background: Epidemiological studies have shown a causal relationship between lung cancer and tuberculosis, especially in patients with tuberculosis, who are more likely to develop lung adenocar-cinoma, but the mechanism of action is not clear. Previous studies have found that EGFR mutation and FHIT methylation levels are higher in pulmonary tuberculosis patients, and this study aims to identify the genetic association of EGFR mutation and FHIT methylation in lung adenocarcinoma and tuberculosis patients. Methods: In patients with lung adenocarcinoma and tuberculosis, epidermal growth factor receptor (EGFR) mutations and methylation status of FHIT gene were analyzed, and the relationship between tuberculosis status and genetic/epigenetic variants was examined. Results: There was a strong correlation between tuberculosis prevalence and EGFR mutation frequency, while the relationship between tuberculosis prevalence and FHIT methylation was weak. There was an inverse correlation between EGFR mutations and FHIT methylation. Conclusion: Tuberculosis may hinder EGFR mutations while increasing the methylation rate of FHIT, resulting in poor response to EGFR inhibitor therapy in patients with lung adenocarcinoma after tuberculosis.
| [1] | Oliver, A.L. (2022) Lung Cancer: Epidemiology and Screening. Surgical Clinics of North America, 102, 335-344. https://doi.org/10.1016/j.suc.2021.12.001 |
| [2] | Deshpand, R., Chandra, M. and Rauthan, A. (2022) Evolving Trends in Lung Cancer: Epidemiology, Diagnosis, and Management. Indian Journal of Cancer, 59, S90-S105. https://doi.org/10.4103/ijc.ijc_52_21 |
| [3] | Houben, R.M.G.J., Esmail, H., Cobelens, F., Williams, C.M.L. and Coussens, A.K. (2022) Tuberculosis Prevalence: Beyond the Tip of the Iceberg. The Lancet Respiratory Medicine, 10, 537-539. https://doi.org/10.1016/s2213-2600(22)00184-9 |
| [4] | Salari, N., Kanjoori, A.H., Hosseinian-Far, A., Hasheminezhad, R., Mansouri, K. and Mohammadi, M. (2023) Global Prevalence of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. Infectious Diseases of Poverty, 12, Article No. 57. https://doi.org/10.1186/s40249-023-01107-x |
| [5] | Liu, Z., Yi, H.E. and Wei, S.U. (2023) Analysis of the Epidemiological Characteristics of Pulmonary Tuberculosis in Kashgar, Xinjiang Uygur Autonomous Region from 2011 to 2020. Journal of Tropical Diseases and Parasitology, 21, 93-97. |
| [6] | Zhang, Y., Wang, X., Liu, N., Wang, S., Wang, X. and Cao, M. (2023) Intervention Effect of New Tuberculosis Control Model on Tuberculosis Incidence in Xinjiang. Infection and Drug Resistance, 16, 7485-7496. https://doi.org/10.2147/idr.s441899 |
| [7] | Wang, L., Teng, Z., Rifhat, R. and Wang, K. (2023) Modelling of a Drug Resistant Tuberculosis for the Contribution of Resistance and Relapse in Xinjiang, China. Discrete and Continuous Dynamical Systems-B, 28, 4167-4189. https://doi.org/10.3934/dcdsb.2023003 |
| [8] | Abdeahad, H., Salehi, M., Yaghoubi, A., Aalami, A.H., Aalami, F. and Soleimanpour, S. (2021) Previous Pulmonary Tuberculosis Enhances the Risk of Lung Cancer: Systematic Reviews and Meta-Analysis. Infectious Diseases, 54, 255-268. https://doi.org/10.1080/23744235.2021.2006772 |
| [9] | Qin, Y., Chen, Y., Chen, J., Xu, K., Xu, F. and Shi, J. (2022) The Relationship between Previous Pulmonary Tuberculosis and Risk of Lung Cancer in the Future. Infectious Agents and Cancer, 17, Article No. 20. https://doi.org/10.1186/s13027-022-00434-2 |
| [10] | Jung, H., Kim, H.S., Kim, J.Y., Sun, J., Ahn, J.S., Ahn, M., et al. (2019) DNA Methylation Loss Promotes Immune Evasion of Tumours with High Mutation and Copy Number Load. Nature Communications, 10, Article No. 4278. https://doi.org/10.1038/s41467-019-12159-9 |
| [11] | Alduais, Y., Zhang, H., Fan, F., Chen, J. and Chen, B. (2023) Non-Small Cell Lung Cancer (NSCLC): A Review of Risk Factors, Diagnosis, and Treatment. Medicine, 102, e32899. https://doi.org/10.1097/md.0000000000032899 |
| [12] | Nooreldeen, R. and Bach, H. (2021) Current and Future Development in Lung Cancer Diagnosis. International Journal of Molecular Sciences, 22, Article 8661. https://doi.org/10.3390/ijms22168661 |
| [13] | Joshi, A., Butle, A., Hait, S., Mishra, R., Trivedi, V., Thorat, R., et al. (2022) Osimertinib for Lung Cancer Cells Harboring Low-Frequency EGFR T790M Mutation. Translational Oncology, 22, Article 101461. https://doi.org/10.1016/j.tranon.2022.101461 |
| [14] | Nakata, S., Sugio, K., Uramoto, H., Oyama, T., Hanagiri, T., Morita, M., et al. (2006) The Methylation Status and Protein Expression of CDH1, p16INK4A, and Fragile Histidine Triad in Nonsmall Cell Lung Carcinoma. Cancer, 106, 2190-2199. https://doi.org/10.1002/cncr.21870 |
| [15] | Zhang, Y., Wang, R., Song, H., Huang, G., Yi, J., Zheng, Y., et al. (2011) Methylation of Multiple Genes as a Candidate Biomarker in Non-Small Cell Lung Cancer. Cancer Letters, 303, 21-28. https://doi.org/10.1016/j.canlet.2010.12.011 |
| [16] | Nishihara, S., Yamaoka, T., Ishikawa, F., Higuchi, K., Hasebe, Y., Manabe, R., et al. (2022) Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. Genes, 13, Article 2183. https://doi.org/10.3390/genes13122183 |
| [17] | Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I.S., Plotnick, D., et al. (2021) Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Research, 81, 4835-4848. https://doi.org/10.1158/0008-5472.can-20-2811 |
| [18] | Talukdar, S., Emdad, L., Das, S.K. and Fisher, P.B. (2020) EGFR: An Essential Receptor Tyrosine Kinase-Regulator of Cancer Stem Cells. Advances in Cancer Research, 147, 161-188. https://doi.org/10.1016/bs.acr.2020.04.003 |
| [19] | Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E. and Tiseo, M. (2019) Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. British Journal of Cancer, 121, 725-737. https://doi.org/10.1038/s41416-019-0573-8 |
| [20] | Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J. and Meng, X. (2021) The Efficacy and Possible Mechanisms of Immune Checkpoint Inhibitors in Treating Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancer Communications, 41, 1314-1330. https://doi.org/10.1002/cac2.12229 |
| [21] | Castellanos, E., Feld, E. and Horn, L. (2017) Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12, 612-623. https://doi.org/10.1016/j.jtho.2016.12.014 |
| [22] | Wu, J., Yu, C., Chang, Y., Yang, C., Shih, J. and Yang, P. (2011) Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer. Clinical Cancer Research, 17, 3812-3821. https://doi.org/10.1158/1078-0432.ccr-10-3408 |
| [23] | Huang, Y., Kong, Y., Wei, Z. and Ye, X. (2022) Image-Guided Thermal Ablation for Patients with Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer. Asia-Pacific Journal of Clinical Oncology, 19, 427-433. https://doi.org/10.1111/ajco.13875 |
| [24] | Paez, J.G., Jänne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004) EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 304, 1497-1500. https://doi.org/10.1126/science.1099314 |
| [25] | Herrera Ortiz, A.F., Garland, M.E. and Almarie, B. (2022) Clinical and Radiological Characteristics to Differentiate between EGFR Exon 21 and Exon 19 Mutations in Patients with Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis. Cureus, 14, e25446. https://doi.org/10.7759/cureus.25446 |
| [26] | He, J., Huang, Z., Han, L., Gong, Y. and Xie, C. (2021) Mechanisms and Management of 3rd-Generation EGFR-TKI Resistance in Advanced Non-Small Cell Lung Cancer (Review). International Journal of Oncology, 59, Article No. 90. https://doi.org/10.3892/ijo.2021.5270 |
| [27] | Harrison, P.T., Vyse, S. and Huang, P.H. (2020) Rare Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer. Seminars in Cancer Biology, 61, 167-179. https://doi.org/10.1016/j.semcancer.2019.09.015 |
| [28] | Bobak, C.A., Abhimanyu, Natarajan, H., Gandhi, T., Grimm, S.L., Nishiguchi, T., et al. (2022) Increased DNA Methylation, Cellular Senescence and Premature Epigenetic Aging in Guinea Pigs and Humans with Tuberculosis. Aging, 14, 2174-2193. https://doi.org/10.18632/aging.203936 |
| [29] | Kwon, M.H., Lee, G.E., Kwon, S.J., Choi, E., Na, M.J., Cho, H.M., et al. (2008) Identification of DNA Methylation Markers for NSCLC Using Hpall-Mspl Methylation Microarray. Tuberculosis and Respiratory Diseases, 65, 495-503. https://doi.org/10.4046/trd.2008.65.6.495 |
| [30] | Sharma, G., Sowpati, D.T., Singh, P., Khan, M.Z., Ganji, R., Upadhyay, S., et al. (2016) Genome-Wide Non-CpG Methylation of the Host Genome during M. tuberculosis Infection. Scientific Reports, 6, Article No. 25006. https://doi.org/10.1038/srep25006 |
| [31] | DeJesus, M.A., Gerrick, E.R., Xu, W., Park, S.W., Long, J.E., Boutte, C.C., et al. (2017) Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. mBio, 8, e02133. https://doi.org/10.1128/mbio.02133-16 |
| [32] | Yuan, G., Flores, N.M., Hausmann, S., Lofgren, S.M., Kharchenko, V., Angulo-Ibanez, M., et al. (2021) Elevated NSD3 Histone Methylation Activity Drives Squamous Cell Lung Cancer. Nature, 590, 504-508. https://doi.org/10.1038/s41586-020-03170-y |
